Show simple item record

dc.contributor.authorDranitsaris, Georgeen_US
dc.contributor.authorLubbe, Martie S.en_US
dc.contributor.authorTruter, Ilseen_US
dc.contributor.authorCottrell, Wayneen_US
dc.contributor.authorSpirovski, Biljanaen_US
dc.identifier.citationDranitsaris, G. et al. 2010. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs . Journal of evaluation in clinical practice, 18(2): 343-351. []en_US
dc.identifier.issn1365-2753 (Online)en_US
dc.description.abstractRationale, aims and objectives  Value‐based pricing has recently been discussed by international bodies as a means to estimate a drug price that is linked to the benefits it offers patients and society. The World Health Organization (WHO) has recommended using three times a country's per capita gross domestic product (GDP) as the threshold for economic value. Using the WHO criteria, pharmacoeconomic modelling was used to illustrate the application of value‐based price towards bevacizumab, a relatively new drug that provides a 1.4‐month survival benefit to patients with metastatic colorectal cancer (mCRC). Methods  A decision model was developed to simulate outcomes in mCRC patients receiving chemotherapy ± bevacizumab. Clinical data were obtained from randomized trials and costs from Canadian cancer centres. Utility estimates were determined by interviewing 24 oncology nurses and pharmacists. A price per dose of bevacizumab was then estimated using a target threshold of $CAD117 000 per quality adjusted life year gained, which is three times the Canadian per capita GDP. Results  For a 1.4‐month survival benefit, a price of $CAD830 per dose would be considered cost‐effective from the Canadian public health care perspective. If the drug were able to improve patient quality of life or survival from 1.4 to 3 months, the drug price could increase to $CAD1560 and $CAD2180 and still be considered cost‐effective. Discussion  The use of the WHO criteria for estimating a value‐based price is feasible, but a balance between what patients/governments can afford to pay and the commercial viability of the product in the reference country would be required
dc.subjectColorectal cancer
dc.subjectCost analysis
dc.subjectDrug pricing
dc.titleThe application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs en_US
dc.contributor.researchID10069712 - Lubbe, Martha Susanna

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record